Dean L. Schorno - Nov 4, 2021 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role: EVP & Chief Financial Officer
Signature: /s/ Dolly Vance (Attorney-in-Fact)
Stock symbol: RIGL
Transactions as of: Nov 4, 2021
Transactions value $: $0
Form type: 4
Date filed: 11/5/2021, 07:06 PM
Next filing: Jan 26, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RIGL	Stock Option (Right to Buy)	Award	$0	+81.3K		$0.00	81.3K	Nov 4, 2021	Common Stock	81.3K	$2.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person was granted a performance-based option to purchase 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On November 4, 2021, it was determined that the performance metric had been met.
F2	The option was fully vested on October 25, 2021, the date the performance metric had been met.

Content

The reporting person was granted a performance-based option to purchase 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On November 4, 2021, it was determined that the performance metric had been met.

The option was fully vested on October 25, 2021, the date the performance metric had been met.